43
DEPARTMENT OF HEALTH AND HUMAN SERVICES • National Institutes of Health • National Cancer Institute The Frederick National Laboratory is a Federally Funded Research and Development Center operated by Leidos Biomedical Research, Inc., for the National Cancer Institute The Ras Initiative: Update for FNLAC October 30 2017 Frank McCormick

The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

  • Upload
    others

  • View
    7

  • Download
    0

Embed Size (px)

Citation preview

Page 1: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

DEPARTMENT OF HEALTH AND HUMAN SERVICES • National Institutes of Health • National Cancer InstituteThe Frederick National Laboratory is a Federally Funded Research and Development Center operated by Leidos Biomedical Research, Inc., for the National Cancer Institute

The Ras Initiative: Update for FNLAC October 30 2017Frank McCormick

Page 2: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

Ras Initiative: Major Goals• Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions

– RAS Assays• Cell-based / biochemical

– Biophysical screens• Tethering / covalent inhibitors

– In silico screens– Partner through cCRADAs– RAS Biology to identify targets– Validation of potential inhibitors

• Molecular description of RAS/RAF signaling complexes in membranes– Biophysical analysis– In silico modeling

2

Page 3: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

RAS Initiative Collaborations: Hub and Spokes

cCRADAs

Strategic Collaborations Academic CollaborationsIndustry Collaborations

RAS Initiative

“The Hub”

3

Page 4: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

RAS cCRADAs

• contractor Cooperative Research and Development Agreement

– Agreement between FNLCR and a private company or university to work together on research and development.

– Allows the contractor to do collaborative research using federal grant monies.

– Provides IP protections to the collaborator.

• Sanofi– All efforts are in-kind, Chemistry supported by Sanofi, Biology shared between Sanofi and FNLCR– Project team: 8 FNLCR, 24 Sanofi

• Kyras– Funds to support 1 FTE equivalent over 2 years– Project team: 4 FNLCR, 5 Kyras

• Beatson– Funds to support 5 FTE equivalents over 2 years– Currently hiring 3 new employees, additional funds are to support existing FNLCR staff

• PharmaArava– Funds to support 2 FTE equivalents over 2 years– Chemistry supported by PharmaAarava, Biology supported by FNLCR

• TheRas– Funds to support 3 FTE equivalents7 over 2 years– Chemistry shared between TheRas and FNLCR, Biology supported by FNLCR

4

Page 5: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

Screening for RAS inhibitors

Page 6: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

Screening for RAS inhibitors

Page 7: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

• 72 hr CellTiter-Glo® cell viability assay• 9 dilutions of each compound were tested• Data collected for 1,402 compounds + controls• RAS-less MEFs tested:

– Kras4B (KrasWT)– KrasG12C

– KrasG12D

– KrasG12V

– KrasG13D

– KrasQ61R

– HrasWT

– BrafV600E

High throughput screening with isogenic cell lines

-2 -1 0 1-2

-1

0

1

S e c o n d ru n ( lo g IC 5 0 )

Fir

st

run

(lo

g I

C5

0)

Screening reproducibility

ERK

Proliferation

MEK

RAF

7

Page 8: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

Receptor Tyrosine Kinase (RTK) inhibitorsHRAS

WTKRASG12D

pERK

ERK

pMEK

MEK

RAS

AZD2171: - + - +

0 .0 1 0 .1 1 1 00 .0 1

0 .1

1

1 0

R T K in h ib ito rs

K ra s W T IC 5 0

Hra

s o

r o

nc

og

en

ic K

ras

IC

50

H ra s

G 1 3 D

B ra f-V 6 0 0 E

G 1 2 D

Q 61R

G 1 2 C

G 1 2V8

Page 9: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

BRAF V600E is sensitive to RAF and MEK inhibitors while oncogenic KRAS is resistant

0 .0 1 0 .1 1 1 00 .0 0 1

0 .0 1

0 .1

1

1 0

R a f in h ib ito rs

K ra s W T IC 5 0

Hra

s o

r o

nc

og

en

ic K

ras

IC

50

H ra s

G 1 3 D

B ra f-V 6 0 0 E

G 1 2 D

Q 61R

G 1 2 C

G 1 2V

0 .0 0 1 0 .0 1 0 .1 1 1 00 .0 0 1

0 .0 1

0 .1

1

1 0

M E K in h ib ito r s

K ra s W T IC 5 0

Hra

s o

r o

nc

og

en

ic K

ras

IC

50

H ra s

G 1 3 D

B ra f-V 6 0 0 E

G 1 2 D

Q 61R

G 1 2 C

G 1 2V

9

Page 10: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

HRAS but not KRAS is sensitive to Farnesyl Transferase Inhibitors

Farnesyl Transferase Inhibitors

LB42708

Page 11: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

Why farnesyl transferase inhibitors don’t work on KRAS

H-ras N-ras K-rasFarnesyltransferase

Farnesyltransferaseinhibitor

Page 12: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

Why farnesyl transferase inhibitors don’t work on KRAS

H-ras N-ras K-ras

Geranylgeranyltransferase

Page 13: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

Blocking RAS processing – targeting C185

farnesyltransferase

geranylgeranyltransferase

13

Page 14: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

• Native or induced Cys within 5-10 Å of target• Protein screened against disulfide fragment library• A reductant is added (typically 2-mercaptoethanol), which allows tuneable

activity• Binding of fragments with high affinity - thermodynamically favoured

Disulfide tethering screen

14

Page 15: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

Compound B9 reacts with Kras4b C185

15

Page 16: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

Targeting KRAS

Covalent

Moderate electrophile

Strong electrophile

994566

FB9

16

Page 17: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

994566 decreases Kras4b membrane localization

Vinculin

KRas

KRas4b G12D(membrane fraction)

Myr-KrasG12D/C185S

(membrane fraction)

994566 (μM)

0 20 30 0 20 30

CTRL 994566, 30µM

17

Page 18: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

2nd generation compounds

Page 19: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

2nd generation compounds

Page 20: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

Targeting C185Yue Yang/Felice Lightstone (LLNL)

H95

20

C185

Page 21: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

Targeting C185

21

Page 22: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

K-Ras FaINNTKsFEDIHHYREQIKRVKDH-Ras FaINNTKsFEDIHQYREQIKRVKDN-Ras FaINNTKsFaDINLYREQIKRVKD

H95

22

Page 23: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

HVR - root-mean-square fluctuation

Yue Yang/Felice Lightstone (LLNL)

23

Page 24: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

Chemistry at FNL

• Multidisciplinary working environment• Work closely with CRO’s for library synthesis• Complex synthesis performed on-site• Four fully equipped Fumehoods• Preparative HPLC and LCMS capabilities• Biotage Isolera One Flash Purification system

24

Page 25: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

25

Page 26: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

In Silico Screens

26

Page 27: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

WT-KRAS-GMPPNP

G12C-GMPPNP G12D-GMPPNP G12V-GMPPNP

G13D-GMPPNP Q61L-GMPPNP Q61R-GMPPNP

Structures of KRAS mutants

Switch-ISwitch-IIP-loop

27

Page 28: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

New pocket in the G12C mutant

Switch-1Switch-2

WT-KRAS bound to GMPPNP and Mg G12C in complex with GMPPNP and Mg

28

Page 29: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

New pocket in G13D mutantSwitch-1Switch-2

G13D in complex with GMPPNP and Mg WT-KRAS bound to GMPPNP and Mg

Larger pocket

29

Page 30: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

New pockets in Q61L mutantSwitch-1Switch-2

Q61L in complex with GMPPNP and Mg WT-KRAS bound to GMPPNP and Mg

30

Page 31: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

31

Q61R K-Ras bound to GAP

RASA1 GAP

Q61R-KRAS

Q61R

Page 32: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS
Page 33: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

In silico screening

• Collaboration with Nir London, Weizmann Institute of Science, Israel.

• A cCRADA established between FNLCR and Weizmann for this work.

• Structures of G12C, G13D and Q61L are being used for in silico screening.

• Hits obtained from in silico screening will be tested for dose-dependent

binding using SPR.

Andy Stephen, RAS Biophysics

• Co-crystallize best binder(s) in complex with KRAS mutant for SAR studies.

Simanshu Dhirendra, RAS Structural Biology

33

Page 34: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

Molecular description of RAS/RAF signaling complexes in membranes

34

Page 35: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

35

• RAS only activates RAF1 at the membrane.

• Molecular mechanism of RAF1 activation by KRAS is unknown

• Is the KRAS:RAF1 complex at the membrane a novel therapeutic target?

• Use a combination of biophysical methods with KRAS and domains of RAF1 to gain structural insight.

• Investigate the lipid specificity of KRAS and RAF1.

• Collaborate with DOE to guide large scale molecular dynamics simulation of KRAS:RAF1 interaction on membrane

RAS signaling happens at the membrane

Page 36: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

36

JDACS4C

Page 37: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

• Develop adaptive resolution MD that investigate KRAS dynamics on membranes• Investigate KRAS-RAF1 dynamics in full MD simulations• Identify potential therapeutic sites in KRAS-RAF1 complexes using automated hypothesis

generation and testing

DOE MD simulationsKRAS dynamics in live cells

KRAS biophysics in reconstituted membrane

37

JDACS4C – Pilot 2

Page 38: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

KRAS molecules on membrane

Halotag K-Ras4b

++++ ++- - - - - -

38

Page 39: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

KRAS4b in plasma membrane – MD simulation

• 20,000 lipids (70x70 nm)• 40 µs pre-equilibration• 64 Ras proteins cluster readily

Helgi Ingólfsson, LLNL

• Associates with and aggregates charged lipids in the membrane

39

Page 40: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

KRAS4b – Follow the lipids

40

Page 41: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

Assessing the pose of KRAS:RBD on membranes• Three possible orientations of PDB 4G0N (HRAS-RBD) fit the neutron reflectivity (NR) data • Orientation #1 agrees with NMR data

NIST Frank Heinrich

RBD

HRAS

31 2

N-terminal

C-terminal

N-terminal

C-terminal

C-terminalN-terminal

N-terminal

C-terminal

Volume Occupancy profile

41

Page 42: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

NMR and LANL MD simulations show similar CRD interaction with the membrane

A BRed residues are peaks that are lost with NDBlue residues are peaks with significant shift

1FAQ

234138

280184

A B

A B

membrane

LANL’s BRAF-CRD: three 1µs

Los Alamos National Lab Tim Travers & Chris Neale 42

Page 43: The Ras Initiative: Update for FNLAC October 30 2017...Ras Initiative: Major Goals • Discover small molecules that bind to RAS directly or disrupt RAS/effector interactions – RAS

Summary

• RAS Initiative has consolidated to two primary focus areas– Directly Targeting KRAS– Understanding the biology of KRAS in the context of the plasma membrane

• Identified a novel class of compounds to specifically target KRAS

• Multiple screens to identify leads are ongoing

• Working with DOE to bridge experimental gaps using computation

• Will partner with biotech, Pharma and NIH to develop leads and push towards clinic